Should Empagliflozin Be Stopped in Acute AKI?
Empagliflozin should be temporarily discontinued during acute kidney injury (AKI), particularly when associated with volume depletion, hemodynamic instability, or acute dehydrating illness, but can generally be continued in stable patients with chronic kidney disease experiencing expected eGFR declines.
Key Decision Framework
When to STOP Empagliflozin:
Mandatory discontinuation scenarios 1, 2:
- Acute dehydrating illness (vomiting, diarrhea, fever) - part of "sick day management"
- Hemodynamic instability requiring escalating vasopressor support
- Volume depletion with symptomatic hypotension
- Suspected diabetic ketoacidosis (DKA) - particularly in insulin-requiring patients
- Suspected Fournier's gangrene or necrotizing fasciitis
- Severe urosepsis or pyelonephritis requiring hospitalization
Consider temporary discontinuation 1, 3:
- Concurrent use of multiple nephrotoxic agents
- Planned contrast administration in unstable patients
- Major surgery with anticipated prolonged NPO status
- eGFR <20 mL/min/1.73 m² (contraindication per FDA label) 2
When to CONTINUE Empagliflozin:
- Expected eGFR decline of 10-25% within first 1-3 months (hemodynamic effect, not true injury)
- Stable chronic kidney disease with eGFR ≥20 mL/min/1.73 m²
- Established heart failure patients who are euvolemic and hemodynamically stable
- Post-AKI recovery phase in stable patients (major trials continued therapy when eGFR fell below initiation thresholds) 4
Critical Distinction: Expected vs. Pathologic Changes
The 2022 ADA/KDIGO consensus emphasizes that SGLT2 inhibitors actually protect against AKI rather than cause it 4. The initial eGFR decline represents beneficial hemodynamic changes (reduced intraglomerular pressure), similar to ACE inhibitors/ARBs 1.
Evidence from major trials 4, 5:
- CREDENCE and DAPA-CKD protocols specified continuation when eGFR fell below initiation thresholds
- EMPEROR-Reduced enrolled patients with eGFR as low as 20 mL/min/1.73 m²
- Trial data show reduced AKI incidence with SGLT2 inhibitors, not increased risk 4, 6
Practical Management Algorithm
Step 1: Assess the clinical context
- Is this acute illness with volume depletion? → STOP temporarily
- Is this expected eGFR decline in stable patient? → CONTINUE
- Is patient hemodynamically unstable? → STOP temporarily
Step 2: Evaluate volume status 2
- Signs of hypovolemia (orthostasis, decreased skin turgor, concentrated urine)
- Concurrent diuretic use (additive effect with SGLT2i)
- Recent fluid losses (GI, fever, poor intake)
Step 3: Check for high-risk scenarios 1
- Insulin use (DKA risk - monitor ketones)
- Multiple nephrotoxic medications
- Baseline eGFR <30 mL/min/1.73 m²
- Active infection requiring antibiotics
Step 4: Monitor appropriately
- Recheck creatinine within 1 week if stopped
- Assess volume status and hemodynamics
- Monitor for ketones if diabetic and acutely ill
Common Pitfalls to Avoid
Stopping for expected eGFR decline: The initial 10-25% eGFR drop is therapeutic, not harmful 1. This reverses after discontinuation and represents the drug's renoprotective mechanism.
Confusing SGLT2i effects with true AKI: FDA warnings about AKI 2 primarily reflect volume depletion scenarios, not direct nephrotoxicity. The drug class actually reduces AKI risk in properly selected patients 4, 6.
Failing to restart after acute illness: Once volume status is restored and patient is stable, empagliflozin should be restarted to maintain cardiovascular and renal benefits 4, 1.
Treating SGLT2i like traditional nephrotoxins: Unlike NSAIDs or aminoglycosides, empagliflozin has proven long-term renoprotective effects 4, 5. The risk-benefit calculation differs fundamentally.
When to Restart
Resume empagliflozin when 1:
- Volume status optimized (euvolemic)
- Hemodynamically stable (off or stable vasopressors)
- Acute illness resolved
- Adequate oral intake established
- eGFR ≥20 mL/min/1.73 m²
The 2022 Canadian guidelines specifically state: "SGLT2i should be stopped temporarily in the setting of concomitant dehydrating illness as part of 'sick day' management" 1 - emphasizing the temporary nature of discontinuation.